Cost-effectiveness of CA125- and age-informed risk-based triage for ovarian cancer detection in primary care
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
In England, current practice is cancer antigen 125 (CA125) testing with pelvic ultrasound scan (USS) if CA125 is ≥35 U/mL for triage of women with suspected ovarian cancer (OC) in primary care. However, OC risk varies with CA125 level and age. The Ovatools model predicts OC risk based on age and CA125 levels to support primary care triage.
Method
We evaluated five alternative triage pathways for suspected OC in primary care, using a decision model. Two CA125-USS sequential pathways used Ovatools risk: 1-3% (subsequent USS) and ≥3% (urgent referral), or age-adjusted CA125 thresholds equivalent to Ovatools risks. Three pathways involved concurrent CA125-USS testing, with referral if abnormal USS or one of the following: (1) Ovatools risk ≥3%, (2) CA125 above the equivalent age-adjusted threshold or (3) CA125 ≥35U/mL. Clinical and cost-effectiveness was compared against current practice for women over and under 50 years of age.
Results
All alternative pathways increased benefits at age ≥50 years, at additional cost. The incremental cost-effectiveness ratios for CA125-USS sequential pathways were below 30,000 British pounds, dropping below 20,000 British pounds if the Ovatools threshold for USS was increased to 1.2-1.4% risk.
Discussion
For women ≥50 years, the Ovatools and equivalent age-adjusted threshold sequential pathways are cost-effective compared to current practice.
